



# PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

### A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

**NAME** : Mr. KAMAL

AGE/ GENDER : 42 YRS/MALE **PATIENT ID** : 1264522

**COLLECTED BY** REG. NO./LAB NO. : 122501270013

REFERRED BY **REGISTRATION DATE** : 27/Jan/2025 10:41 AM BARCODE NO. : 12506709 **COLLECTION DATE** : 27/Jan/2025 11:03AM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 27/Jan/2025 11:51AM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Value Unit **Biological Reference interval Test Name** 

## **HAEMATOLOGY HAEMOGLOBIN (HB)**

HAEMOGLOBIN (HB) 15.4 12.0 - 17.0 gm/dL

by CALORIMETRIC

**INTERPRETATION:-**Hemoglobin is the protein molecule in red blood cells that carries oxygen from the lungs to the bodys tissues and returns carbon dioxide from the tissues back to the lungs.

A low hemoglobin level is referred to as ANEMIA or low red blood count.

#### ANEMIA (DECRESED HAEMOGLOBIN):

1) Loss of blood (traumatic injury, surgery, bleeding, colon cancer or stomach ulcer)

2) Nutritional deficiency (iron, vitamin B12, folate)

- 3) Bone marrow problems (replacement of bone marrow by cancer)
- 4) Suppression by red blood cell synthesis by chemotherapy drugs

5) Kidney failure

6) Abnormal hemoglobin structure (sickle cell anemia or thalassemia).

#### POLYCYTHEMIA (INCREASED HAEMOGLOBIN):

- 1) People in higher altitudes (Physiological)
- 2) Smoking (Secondary Polycythemia)
- 3) Dehydration produces a falsely rise in hemoglobin due to increased haemoconcentration
- 4) Advanced lung disease (for example, emphysema)
- 5) Certain tumors
- 6) A disorder of the bone marrow known as polycythemia rubra vera,
- 7) Abuse of the drug erythropoetin (Epogen) by athletes for blood doping purposes (increasing the amount of oxygen available to the body by chemically raising the production of red blood cells).

NOTE: TEST CONDUCTED ON EDTA WHOLE BLOOD



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)

CLIENT CODE.



# PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

### A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

**NAME** : Mr. KAMAL

AGE/ GENDER : 42 YRS/MALE **PATIENT ID** : 1264522

**COLLECTED BY** REG. NO./LAB NO. : 122501270013

REFERRED BY **REGISTRATION DATE** : 27/Jan/2025 10:40 AM BARCODE NO. **COLLECTION DATE** : 27/Jan/2025 11:03AM : 12506709

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

: P.K.R JAIN HEALTHCARE INSTITUTE

**Value** Unit **Test Name Biological Reference interval** 

REPORTING DATE

### CLINICAL CHEMISTRY/BIOCHEMISTRY

**LIPID PROFILE: BASIC** 

CHOLESTEROL TOTAL: SERUM OPTIMAL: < 200.0 203.81<sup>H</sup> mg/dL

by CHOLESTEROL OXIDASE PAP BORDERLINE HIGH: 200.0 -

239.0

HIGH CHOLESTEROL: > OR =

240.0

: 27/Jan/2025 11:51AM

TRIGLYCERIDES: SERUM OPTIMAL: < 150.0 167.17<sup>H</sup> mg/dL by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)

BORDERLINE HIGH: 150.0 -

199.0

HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0

LOW HDL: < 30.0

HDL CHOLESTEROL (DIRECT): SERUM 38.21 mg/dL

by SELECTIVE INHIBITION BORDERLINE HIGH HDL: 30.0 -

60.0  $HIGH\ HDL: > OR = 60.0$ 

LDL CHOLESTEROL: SERUM OPTIMAL: < 100.0

132.17<sup>H</sup> mg/dL by CALCULATED, SPECTROPHOTOMETRY

ABOVE OPTIMAL: 100.0 - 129.0

BORDERLINE HIGH: 130.0 -

HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0

NON HDL CHOLESTEROL: SERUM 165.6<sup>H</sup> mg/dL OPTIMAL: < 130.0

by CALCULATED, SPECTROPHOTOMETRY ABOVE OPTIMAL: 130.0 - 159.0

BORDERLINE HIGH: 160.0 -

HIGH: 190.0 - 219.0

VERY HIGH: > OR = 220.0

mg/dL VLDL CHOLESTEROL: SERUM 33.43 0.00 - 45.00by CALCULATED. SPECTROPHOTOMETRY

TOTAL LIPIDS: SERUM 574.79 350.00 - 700.00 mg/dL

by CALCULATED, SPECTROPHOTOMETRY 5.33<sup>H</sup> CHOLESTEROL/HDL RATIO: SERUM RATIO LOW RISK: 3.30 - 4.40 by CALCULATED, SPECTROPHOTOMETRY

AVERAGE RISK: 4.50 - 7.0



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







# PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

### A PIONEER DIAGNOSTIC CENTRE

**NAME** : Mr. KAMAL

AGE/ GENDER : 42 YRS/MALE **PATIENT ID** : 1264522

**COLLECTED BY** REG. NO./LAB NO. : 122501270013

REFERRED BY **REGISTRATION DATE** : 27/Jan/2025 10:40 AM BARCODE NO. **COLLECTION DATE** : 27/Jan/2025 11:03AM : 12506709 CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 27/Jan/2025 11:51AM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name	Value	Unit	Biological Reference interval
LDL/HDL RATIO: SERUM	3.46 <sup>H</sup>	RATIO	MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0 LOW RISK: 0.50 - 3.0
by CALCULATED, SPECTROPHOTOMETRY	3.40	Willo	MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0
TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	4.38	RATIO	3.00 - 5.00

INTERPRETATION:

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for

Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.

4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

\*\*\* End Of Report \*\*\*



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)